The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C02 | Antihypertensives | |
| 3 | C02C | Antiadrenergic agents, peripherally acting | |
| 4 | C02CA | Alpha-adrenoreceptor antagonists | |
| 5 | C02CA06 | Urapidil |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.12 g |
| PAREN - Parenteral | 50 mg |
| Active Ingredient | Description | |
|---|---|---|
| Urapidil |
Urapidil is a α1-adrenoceptor antagonist and 5-HT1A receptor agonist and consequently inhibits the vasoconstrictor effect of catecholamines. It interacts with peripheral α1-adrenoceptors and central 5-HT1A receptors to produce vasodilation without sympathetic activation. |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
